The anti-leukemic compound NL-1 inhibits the growth of REH and REH/Ara-C cells with IC50 values of 47.35 µM and 56.26 µM, respectively, by acting as a mitoNEET inhibitor. Additionally, NL-1 induces leukemia cell death by activating the autophagy pathway.
| Catalog Number | I017526 |
| CAS Number | 188532-26-5 |
| Molecular Formula | C₁₈H₂₅NO₃S |
| Purity | 95% |
| Storage | -20°C |
| IUPAC Name | 5-[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione |
| InChI | InChI=1S/C18H25NO3S/c1-17(2,3)11-7-10(8-12(14(11)20)18(4,5)6)9-13-15(21)19-16(22)23-13/h7-8,13,20H,9H2,1-6H3,(H,19,21,22) |
| InChIKey | QDYYSPGKYXWGSL-UHFFFAOYSA-N |
| SMILES | CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)CC2C(=O)NC(=O)S2 |
| Reference | [1]. Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34. |
